ST. LOUIS, Jan. 27, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Fuwai Central China Cardiovascular Hospital has become the first in central China to establish a robotic electrophysiology program with installation of Stereotaxis’ Robotic Magnetic Navigation technology. Chief physicians for arrhythmia treatment, Dr. Chen Ke and Dr. Song Weifeng, successfully performed their first robotic cardiac ablation procedure, treating a patient who suffered from a complex ventricular arrhythmia. “I am very proud of our team for successfully completing our first robotic ablation procedure in under one...